InSilico Medicine Cayman TopCo
Total Valuation
EURAs of June 30, 2026, InSilico Medicine Cayman TopCo carries a market capitalization of 2.57B, placing it among publicly traded companies globally. Its enterprise value stands at 2.07B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.57B |
| Enterprise Value | 2.07B |
Important Dates
InSilico Medicine Cayman TopCo's next confirmed earnings release is scheduled for March 29, 2027.
| Earnings Date | 3/29/2027 |
Share Statistics
As of June 30, 2026, InSilico Medicine Cayman TopCo has 575.84M shares outstanding.
| Shares Outstanding | 575.84M |
Valuation Ratios
These figures are as of June 30, 2026.
| PB Ratio | 5.36 |
| P/TBV Ratio | 5.37 |
Financial Position
As of June 30, 2026, InSilico Medicine Cayman TopCo maintains a current ratio of 8.70, meaning it holds 8.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 8.70 |
| Quick Ratio | 8.47 |
| Debt / Equity | 3.59 |
Financial Efficiency
These figures cover the twelve months ended June 30, 2026.
| Employee Count | 317.00 |
Stock Price Statistics
EURThese figures are as of the close on October 22, 2026.
| 50-Day Moving Average | 5.53 |
Balance Sheet
EURAs of June 30, 2026, InSilico Medicine Cayman TopCo holds 511.89M in cash and equivalents against 17.20M in total debt, resulting in a net debt position of -300.17M. Total book value stands at 478.84M, with working capital of 465.67M providing operational flexibility.
| Cash & Cash Equivalents | 511.89M |
| Total Debt | 17.20M |
| Net Debt | -300.17M |
| Equity (Book Value) | 478.84M |
| Book Value Per Share | 0.83 |
| Working Capital | 465.67M |